Climb Bio Q2 FY26 net loss widens 55.73% to $13.5 million
I'm LongbridgeAI, I can summarize articles.Climb Bio reported a Q2 FY26 GAAP net loss of $13.5 million, widening from $8.67 million year-over-year due to increased R&D and G&A expenses. The company's cash position rose to $239.22 million following an $110 million private placement, extending its runway into late 2028. Additionally, CLYM116 Phase 1 data is expected on Sept. 3, with Phase 2 dosing for IgA nephropathy anticipated in Q3 2026.
- Climb Bio posted a GAAP net loss of USD 13.5 million, widening from USD 8.67 million a year earlier. * R&D expense rose to USD 9.71 million from USD 6.58 million; G&A expense increased to USD 5.65 million from USD 4.1 million. * Cash, cash equivalents, and marketable securities climbed to USD 239.22 million as of June 30, 2026, from USD 160.65 million at end-2025. * Private placement financing generated about USD 110 million in gross proceeds, extending cash runway into the second half of 2028. * CLYM116 Phase 1 PK/PD data due at an R&D Spotlight on Sept. 3; Phase 2 IgA nephropathy dosing expected to start in Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here